UCBJY News and Press, UCB SA ADR

2026-03-15 23:25:00 ET The following segment was excerpted from the PGIM Jennison Health Sciences Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: PGIM Jennison Health Sciences Fund Q4 2025 Key ...

2026-03-11 08:31:57 ET More on AbbVie, UCB SA AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript AbbVie: Stabilizes Near $233 While Testing Resistance AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcri...

2026-02-28 00:47:47 ET UCB SA (UCBJY) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST Company Participants Antje Witte - Head of Investor Relations Jean-Christophe Tellier - CEO & Executive Director Emmanuel Caeymaex - Executive Vice President of Patient Ev...

2026-02-26 01:51:02 ET More on UCB SA UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Seeking Alpha’s Quant Rating on UCB SA Histor...

2026-01-14 12:46:00 ET UCB SA (UCBJY) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-10 10:26:49 ET Introduction AstraZeneca ( AZN ) is looking to be the first biopharma to throw off the cloak of cyclicality due to their work in optimizing the commercial and pipeline asset base. Despite being able to leverage experience and economies of scale, big pharma...

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder PR Newswire Seizure reduction : phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistical...

UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting PR Newswire Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including the presentation of positive primary efficacy and safety results from a phase...

/C O R R E C T I O N -- UCB/ PR Newswire In the news release, U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d), issued Nov. 3, 2025 by UCB over PR Newswire, we are...

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) PR Newswire Approved indication:  KYGEVVI ® (doxecitine and doxribtimine) powder for oral solution (2g/2g...